Literature DB >> 19152069

Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women.

Kenjiro Sawada1, Ken-Ichirou Morishige, Yukihiro Nishio, Jun Hayakawa, Seiji Mabuchi, Aki Isobe, Seiji Ogata, Masahiro Sakata, Masahide Ohmichi, Tadashi Kimura.   

Abstract

A forearm fracture (Colles' fracture) is often the first sign of osteoporosis and may suggest underlying skeletal fragility. Therefore, establishment of a more accurate and reliable method for the measurement of bone mineral density (BMD) at the distal radius would be beneficial for patients who suffer from osteoporosis. The objective of this study was to evaluate the usefulness of peripheral quantitative computed tomography (pQCT) to monitor the response to alendronate therapy at the distal radius in early postmenopausal Japanese women. Thirty-two early postmenopausal women who were diagnosed with osteoporosis or osteopenia were randomized to either alendronate or control treatment. We analyzed the BMD of the distal radius by pQCT, lumbar spine by dual-energy X-ray absorptiometry (DXA) and the biochemical markers of bone turnover (deoxypyridinoline) at baseline, 3, 6 and 12 months. The control group showed a significant decrease from baseline in the trabecular BMD of the radius at 12 months (3.5 +/- 3.7%; p < 0.01), whereas the alendronate group showed a significant increase (4.3 +/- 8.1%). The changes in the trabecular BMD of the radius between the alendronate and control groups were statistically different at 6 and 12 months (p < 0.01). However, in the total BMD at the diaphysis of the radius, no significant differences were seen in the changes in bone densities between the alendronate and control groups after 1 year of treatment. pQCT detected significant differences in BMD of the radius in early postmenopausal women after 1 year of treatment with alendronate. Collectively, our preliminary clinical trial showed that pQCT might be useful to monitor response to alendronate therapy, especially at the radius, and it might explain why alendronate prevents Colles' fracture.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152069     DOI: 10.1007/s00774-008-0025-7

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

Review 1.  Treatment of postmenopausal osteoporosis.

Authors:  R Eastell
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

2.  Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.

Authors:  Kenjiro Sawada; Ken-Ichirou Morishige; Masahide Ohmichi; Yukihiro Nishio; Toshiya Yamamoto; Jun Hayakawa; Seiji Mabuchi; Aki Isobe; Hiroshi Sasaki; Masahiro Sakata; Keiichi Tasaka; Yuji Murata
Journal:  Maturitas       Date:  2006-09-28       Impact factor: 4.342

3.  Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.

Authors:  M L Bouxsein; R A Parker; S L Greenspan
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

4.  Differential effects of menopause and metabolic disease on trabecular and cortical bone assessed by peripheral quantitative computed tomography (pQCT).

Authors:  K Tsurusaki; M Ito; K Hayashi
Journal:  Br J Radiol       Date:  2000-01       Impact factor: 3.039

5.  Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

Authors:  J R Tucci; R P Tonino; R D Emkey; C A Peverly; U Kher; A C Santora
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

6.  Cut-off values determined for vertebral fracture by peripheral quantitative computed tomography in Japanese women.

Authors:  I Gorai; K Nonaka; H Kishimoto; H Sakata; Y Fujii; T Fujita
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

7.  Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate.

Authors:  S A Earnshaw; S A Cawte; A Worley; D J Hosking
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

Review 8.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Highly precise peripheral quantitative computed tomography for the evaluation of bone density, loss of bone density and structures. Consequences for prophylaxis and treatment.

Authors:  M A Dambacher; M Neff; R Kissling; L Qin
Journal:  Drugs Aging       Date:  1998       Impact factor: 3.923

10.  Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis.

Authors:  Ling Qin; Wingyee Choy; Szeki Au; Musei Fan; Pingchung Leung
Journal:  J Orthop Surg Res       Date:  2007-05-21       Impact factor: 2.359

View more
  2 in total

Review 1.  Surgical treatment options in patients with impaired bone quality.

Authors:  Norman A Johanson; Jody Litrenta; Jay M Zampini; Frederic Kleinbart; Haviva M Goldman
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

2.  Analysis of bone mineral density distribution at trabecular bones in thoracic and lumbar vertebrae using X-ray CT images.

Authors:  Tatsuro Hayashi; Huayue Chen; Kei Miyamoto; Xiangrong Zhou; Takeshi Hara; Ryujiro Yokoyama; Masayuki Kanematsu; Hiroaki Hoshi; Hiroshi Fujita
Journal:  J Bone Miner Metab       Date:  2010-07-16       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.